Ulrich Keilholz
German Cancer Research Center(DE)Heidelberg University(DE)Humboldt-Universität zu Berlin(DE)German Cancer Society(DE)Charité - Universitätsmedizin Berlin(DE)
Publications by Year
Research Areas
Immunotherapy and Immune Responses, Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations, Cutaneous Melanoma Detection and Management, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study(2018)1,654 cited
- → Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial(2008)642 cited
- → Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(2019)615 cited
- → Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects(2011)578 cited
- → Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma(2009)542 cited
- → Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial